"Ciramadol"

,hw,kw. 3 exp narcotic analgesic agent/ 4 exp Analgesics, Opioid/ 5 (acetorphine or acetylcodeine or acetylmethadol or Alfentanil or Alphaprodine or anileridine or apadoline or azidomorphine or benzhydrocodone or bezitramide or bremazocine or "Brompton mixture" or Buprenorphine or Butorphanol or ciramadol or cocodamol or Codeine or codydramol or conorfone or cyclazocine or Dextromoramide

or acetylmethadol or Alfentanil or Alphaprodine or anileridine or apadoline or azidomorphine or benzhydrocodone or bezitramide or bremazocine or "Brompton mixture" or Buprenorphine or Butorphanol or ciramadol or cocodamol or Codeine or codydramol or conorfone or cyclazocine or Dextromoramide or Dextropropoxyphene or dextrorphan or dezocine or diamorphine or diconal or dihydrocodeine or dihydroetorphine

Comparative evaluation of ciramadol (WY-15.705), morphine and placebo for treatment of postoperative pain. The efficacy and safety of intramuscular ciramadol to alleviate postoperative pain was compared to morphine in a double-blind placebo controlled study of 100 patients. Postoperative analgesia was assessed using a visual analog scale and two categorical measurements. Two dose levels of ciramadol (30 and 60 mg) were compared to morphine (5 and 10 mg). A valid dose-response curve was obtained for both drugs with no significant deviation from parallelism. Compared to morphine 10 mg, ciramadol 60 mg induced a faster onset of analgesia and showed a longer lasting effect as deduced from the pain intensity difference and pain analog intensity difference time-effect curves (P less than 0.01

Comparison of the analgesic efficacy and safety oral ciramadol, codeine, and placebo in patients with chronic cancer pain. Ciramadol is a new opioid agonist-antagonist analgesic with low potential for dependency. Forty-three patients with moderate to severe chronic pain from primary or metastatic malignancy of the bone or major organs were enrolled in a randomized double-blind study that compared orally administered ciramadol (30 mg or 90 mg) to codeine (60 mg) and placebo. A single-dose, four-way crossover design, with a randomized Latin-square treatment sequence, was used. Data for 40 patients who received the above four study medications were included in the final statistical analysis of efficacy. Analgesic efficacy was measured at 0, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, and 6.0 hours, using

A double-blind comparison of multiple intramuscular doses of ciramadol, morphine, and placebo for the treatment of postoperative pain. Ciramadol, an agonist-antagonist analgesic (in intramuscular doses of 30 and 60 mg) was compared with 10 mg of morphine and placebo in a double-blind, parallel study in 160 patients with postoperative pain. The patients were assigned randomly to one of the four scales. The mean cumulative efficacy scores for the initial dose evaluation were highest for 60 mg of ciramadol; however, patients' overall evaluations of therapy were highest in the morphine group. Nausea and vomiting were the most frequent adverse experiences (15-25% incidence); however, there were no statistically significant differences between groups in their occurrence. A greater percentage (P

Double-blind comparison of the analgesic potency of ciramadol, codeine and placebo against postsurgical pain in ambulant patients. The efficacy and safety of ciramadol (Cir) as an analgesic in relieving moderate to severe pain after oral surgery has been studied in 79 patients randomly assigned to receive single oral doses of Cir 15, 30 or 60 mg, codeine 60 mg or placebo. During the 6-hour observation period, the three ciramadol-treated groups indicated greater pain relief than the codeine 60 mg or placebo groups. In general, Cir 60 mg was significantly more effective than codeine 60 mg, and all doses of Cir were superior to placebo. The proportion of patients in each Cir group reporting adverse experiences was significantly higher than in either the placebo or codeine groups

The effect of food on ciramadol bioavailability in normal subjects. Eleven healthy volunteers completed a study to compare the relative bioavailability to orally administered ciramadol in a fasting versus postprandial state. A single oral dose of 30 mg of ciramadol was administered on two separate occasions, 2 weeks apart, in a randomized crossover study. A mono- or biexponential pharmacokinetic . It is thus concluded that ingestion of food has no effect on the extent of absorption of ciramadol; however, food may alter its rate of absorption.

Double-blind comparison of the analgesic response to oral ciramadol (WY-15.705) and pentazocine in post-operative pain. The efficacy and safety of oral ciramadol, a synthetic partial agonist-antagonist analgesic, in rapid control of postoperative pain was compared with oral pentazocine in a double blind study in 46 patients. Ciramadol 20 mg and 60 mg and pentazocine 50 mg had a rapid analgesic effect, peaking within one hour. Although a similar pattern of activity was observed for ciramadol 20 mg and pentazocine 50 mg, ciramadol 60 mg provided significantly better and longer lasting pain relief (P less than 0.02). Side effects included sedation and sweating, which occurred with a similar frequency in the various treatment groups. Oral ciramadol appears to be a safe and highly effective

Analgesic effect of ciramadol in patients with chronic pain. A double-blind, crossover study was carried out in 15 patients with chronic pain due to cancer to assess the effectiveness of two different doses of a new analgesic, ciramadol, compared with placebo. Patients received single oral doses of the three medications, in random order, on successive days. Assessments of pain intensity and relief were made on a 4-point rating scale at hourly intervals for 4 hours after the dose. The results showed that ciramadol produced significantly more pain relief than did placebo and this analgesic effect increased with the dose administered. Peak activity was observed at about 2 hours, and pain relief was still marked at 4 hours. No side-effects were reported.

Comparison of three doses of oral ciramadol and placebo for the treatment of moderate to severe postoperative pain. Ciramadol, 20, 40, or 60 mg, or a placebo was administered orally, double blind, to patients complaining of moderate (N = 89) or severe (N = 80) postoperative pain to determine the lowest effective dose. The highest dose used for moderate pain, 40 mg, was statistically more effective than placebo as measured by pain intensity differences and pain relief scores. The highest dose used to treat severe pain, 60 mg, was also more effective statistically than placebo and the lower doses of ciramadol at certain points during the 6-hour observation period. Drowsiness was minimal, and side effects were infrequent and mild in intensity. We conclude that 40 mg ciramadol for moderate

Ciramadol--a new synthetic analgesic. A double-blind comparison with oral codeine for postoperative pain relief. One hundred and eighty patients (American Society of Anesthesiologists rating 1-2) received one of three oral analgesics--ciramadol (Wy. 15705) 20 mg, ciramadol 60 mg or codeine 60 mg--on a double-blind random basis for the relief of pain 24-48 hours after major general surgical , gynaecological or orthopaedic operations. All three analgesics proved equally effective and caused mild sedation only. No patient showed signs of clinical cardiorespiratory depression, and other side-effects were infrequent. Ciramadol may therefore prove a useful clinical alternative to conventional oral analgesics provided its lack of respiratory depressant properties and addiction potential in monkeys can

A double-blind trial of single-dose ciramadol for the treatment of post-episiotomy pain. A randomized double-blind trial was carried out in 54 women to evaluate the effectiveness of ciramadol in a single (60 or 30 mg) oral dose regimen, compared with 60 mg codeine and placebo, in the treatment of post-episiotomy pain. Ciramadol gave a significantly better analgesic effect, at both 2 and 6 hours

An open comparative trial of three doses of ciramadol used intravenously in renal colic. In an open investigation, ciramadol, a partial agonist opioid, was found to be a potent analgesic when given intravenously in patients experiencing renal colic. Single intravenous doses of 20, 30 and 40 mg of ciramadol were given to 11, 11 and 12 patients with renal colic, respectively, and good pain relief was obtained in 10, 11 and 10 patients, respectively. Vomiting and nausea occurred in 9 patients, 4 in the 20 mg group, 2 in the 30 mg group and 3 in the 40 mg group. This adverse effect was related to standing and walking following the ciramadol injection.

Comparative evaluation of morphine, pentazocine and ciramadol in postaddicts. The subjective, physiological and behavioral effects of morphine, pentazocine and ciramadol, an opioid agonist/antagonist, were studied in adult male nondependent opioid abusers living on a clinical research ward. Fifteen subjects were assigned randomly to one of three groups. Each group received, by i.m. injection , placebo and three doses of one active drug, twice in randomized block order under double-blind conditions in 4.5-hr experimental sessions. Physiological measures did not differentiate between the three drugs. All three drugs decreased respiratory rate and pupil diameter and increased blood pressure. However, morphine, ciramadol and pentazocine produced different profiles on the subjective effect

Oral ciramadol: a new analgesic for postoperative pain. Ciramadol, a new synthetic narcotic agonist-antagonist analgesic, was compared in 30 and 60 mg doses with pentazocine 50 mg, aspirin 650 mg, and placebo in the treatment of 153 patients with postoperative pain. All drugs were administered between six and 72 hours after surgery. Analgesic efficacy was assessed for six hours after study drug administration using verbal pain intensity, analog pain intensity, and verbal pain relief scales. Significantly (P less than .05) higher analgesic efficacy scores were seen with ciramadol 30 mg than with pentazocine 50 mg and placebo at most of the evaluation points. Doses of ciramadol 30 mg were significantly (P less than .05) more effective than aspirin 650 mg at several time periods, and ciramadol 60 mg

Intramuscularly administered ciramadol for management of postoperative pain: a comparative study. Efficacy and safety of the analgesic ciramadol in the management of postoperative pain was evaluated in 139 healthy patients given single, double-blind, intramuscular injections of either 30 mg ciramadol, 60 mg ciramadol, 10 mg morphine or 0.9% saline on the first or second postoperative day . Differences in pain intensity and relief of pain, changes from baseline on a pain analog scale, percentage of patients with moderate or greater pain relief, and cumulative treatment failures were measured for 6 hours after injection. Morphine proved to be superior to all other treatments. Neither dose of ciramadol could be statistically differentiated from placebo. During the first hour after administration

A double-blind comparison of orally administered ciramadol and codeine for relief of postoperative pain. Ciramadol, a new analgesic with mixed narcotic agonist-antagonist actions, was compared with codeine and placebo in a double-blind study in 343 patients with postoperative pain. The patients received a single oral dose of either 30 or 60 mg of ciramadol, 60 mg of codeine, or placebo . As indicated by three efficacy measures (verbal and visual analog pain scores and pain relief scores), the three active treatments were superior to placebo in relieving pain, and 30 and 60 mg of ciramadol generally were equivalent and superior, respectively, to 60 mg of codeine. The group who took 60 mg of ciramadol had a significantly (P less than .05) lower cumulative remedication frequency than

Hemodynamic and respiratory effects of dezocine, ciramadol, and morphine. The hemodynamic and respiratory effects of dezocine and ciramadol, two agonist-antagonist analgesics, were compared with those of morphine in 30 patients undergoing diagnostic cardiac catheterization. Each subject received a single intravenous dose of dezocine (0.125 mg/kg), ciramadol (0.6 mg/kg), or morphine (0.125 mg/kg ) in a double-blind fashion. Hemodynamic and respiratory parameters were measured at baseline and 5, 10, and 20 minutes after dosing. Dezocine increased the cardiac index (CI; 2.67 to 2.92 L/min/m2), stroke volume index (SVI; 43.6 to 47.6 ml/beat/m2), left ventricular stroke work index (LVSWI; 57.4 to 64.7 gm-m/m2), and pulmonary vascular resistance (PVR; 105.6 to 154.0 dynes X sec/cm5). Ciramadol increased